GLP-1 News — Week of November 2, 2026
The GLP-1 stories that mattered this week — what happened, and what each one means for you if you're using or considering these medications. Every story links to its primary source, and nothing here is influenced by advertisers.
Novo Nordisk Q3 results show rapid Wegovy pill uptake and firm US obesity lead
Novo Nordisk’s Q3 2026 report shows obesity and GLP-1 drugs remain the company’s main growth driver, with adjusted sales up 4 percent and operating profit up 27 percent at constant exchange rates. The Wegovy pill generated about 0.8 billion US dollars in Q3 sales after launches in the US and abroad, and the Wegovy franchise held more than half of new branded obesity prescriptions in the US, alongside ongoing rollout of higher-dose Ozempic and Wegovy pens internationally. (2026-11-04)
What this means for you: You should expect Wegovy and Ozempic, including oral options, to stay widely promoted and increasingly available, with Novo Nordisk investing to expand supply and access rather than pulling back. There is no new price cut this week, but the strong focus on obesity makes it more likely that insurers will keep building coverage pathways ahead of the already-announced 2027 list-price reductions.
Source: Novo Nordisk
Related on Metabolic Ledger: /cost/insurance-coverage-glp1
Novo Nordisk keeps 2027 US list-price cuts for Wegovy, Ozempic, and Rybelsus on the table
In earnings discussions that revisited a February 2026 announcement, Novo Nordisk again tied its obesity-growth story to planned US list-price cuts starting January 1, 2027. Under that plan, Wegovy injections and its 25 mg tablet would see list prices roughly halved to about 675 US dollars, while Ozempic and Rybelsus list prices would fall by about 35 percent. (2026-02-24)
What this means for you: Nothing about what you pay changes in late 2026, but you can plan around the expectation that list prices for semaglutide products will be meaningfully lower in just over a year. If you are uninsured, on a high-deductible plan, or designing benefits for 2027, this is a key signal to revisit GLP-1 coverage and budgeting for that year.
Source: Novo Nordisk
Related on Metabolic Ledger: /cost/wegovy-without-insurance
Ozempic pill rollout in the US gains traction, Novo Nordisk Q3 filing shows
Novo Nordisk’s detailed Q3 2026 investor report confirms that the Ozempic pill for adults with type 2 diabetes has been available nationwide in the US since May 4, 2026. The company reports encouraging use, with weekly new prescriptions for the oral peptide GLP-1 roughly double prior levels when oral semaglutide was sold as Rybelsus. (2026-11-04)
What this means for you: If you have type 2 diabetes and prefer to avoid injections, an oral GLP-1 is now firmly established in US practice rather than an experimental niche. You may find that more insurers, clinics, and prior authorization teams are familiar with Ozempic pill now, so it can be worth revisiting it if you were previously told it was too new or not yet on formulary.
Source: Novo Nordisk
Related on Metabolic Ledger: /drugs/rybelsus-vs-wegovy
Lilly Q3 2026 update underlines obesity pipeline push, including EloraTZP
Eli Lilly’s Q3 2026 earnings release highlights strong performance of its existing obesity drugs and renewed focus on its pipeline. The company reported Phase 2 data for EloraTZP, a combination that includes tirzepatide, in adults with obesity and type 2 diabetes and said Phase 3 trials are slated to begin in Q4 2026, alongside continued investment in manufacturing and research for obesity and metabolic diseases. (2026-10-29)
What this means for you: Your access to Mounjaro or Zepbound does not change this week, but Lilly’s spending on new agents signals that more GLP-1–based options, possibly with different strengths or side-effect patterns, are coming in the next few years. If you are on long-term injectable therapy, it is reasonable to plan for a landscape where switching to newer combinations may become an option later.
Source: Eli Lilly
Related on Metabolic Ledger: /drugs/best-glp1-for-weight-loss
No new FDA GLP-1 safety alerts, compounding crackdowns, or shortage changes this week
A review of FDA drug alerts and policy pages shows no new GLP-1-specific warning letters, shortage listings, or compounding rules between October 30 and November 6, 2026. Earlier 2026 policies remain in place, including FDA concerns about unapproved and compounded semaglutide and tirzepatide, the proposal to remove these drugs from the 503B bulks list, and prior statements that branded semaglutide injection shortages have been resolved. (2026-04-30)
What this means for you: If you are using compounded GLP-1s, the regulatory pressure you face is unchanged this week but still trending against long-term access to bulk-powder products. You should continue planning for a possible forced transition to brand-name drugs or different pharmacies as FDA proposals move toward final rules and state boards keep enforcing existing standards.
Source: FDA
Related on Metabolic Ledger: /regulatory/fda-compounding-cliff